Pérez-Santos, Martín2020-11-272020-11-272020-05-21Pérez-Santos M. miRNA let-7b inhibitors by treatment of diabetic retinopathy: evaluation patent US2019093106. Alianzas y Tendencias BUAP [Internet]. 2020;5(18):1–7. Available from: https://www.aytbuap.mx/publicaciones#h.n833pt4qitm32594-06272594-0627https://www.aytbuap.mx/aytbuap-518/mirna-let-7b-inhibitors-by-treatment-of-diabetic-retinopathyhttps://hdl.handle.net/20.500.12371/9407Introduction: diabetic retinopathy is a clinical complication that affects to a 93 million people suffering from diabetes and is responsible for more hospitalizations than any other complication of diabetes. Authors of US2019093106 patent propose a method for treatment of diabetic retinopathy. Areas covered: US2019093106 describes a method that consists of the administration of inhibitor of miRNA let-7b, in patients with diabetic retinopathy; additionally describe a method to inhibiting the effects of increased levels or activity of miRNA let-7b. Expert opinion: The results pre-clinical trials support the therapy’s efficacy; however, the invention is not new considering art state, whereby, new studies will be necessary to determine other administration routes, e.g. topical, dose and time of administration.engmiRNA let-7bdiabetic retinopathypatentdiabetesinhibitorArtículo